[#item_full_content]
CHICAGO–(BUSINESS WIRE)–Grove Biopharma, a private biotechnology company engineering protein-like polymers (PLPs) – a new class of multifunctional biologics designed to address the most challenging intracellular drug targets – today announced the publication of preclinical results demonstrating targeted degradation of two key oncogenic drivers enabled via its Bionic Biologics platform. The peer-reviewed study, titled “Heterobifunctional proteomimetic polymers for targeted degradation of MYC a